Save Product
Product Details
Source
Biotinylated Monoclonal Anti-Bevacizumab Antibody, Mouse IgG1 (AY13) (Cat. No. BEB-BY13) is a mouse monoclonal antibody produced from a hybridoma generated by fusion of SP2/0 myeloma cells with mouse B lymphocytes.
Antibody Type
Hybridoma Monoclonal
Clone
AY13
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Immunogen
Bevacizumab
Conjugate
Biotinylated
Specificity
AY13 is an inhibitory anti-idiotype monoclonal antibody that specifically recognizes Bevacizumab. No detectable binding to the tested human IgG1 controls, Adalimumab, Cetuximab, or VEGF165 was observed under the tested conditions. AY13 inhibits the binding of Bevacizumab to VEGF165.
Application
ApplicationRecommended Use / PerformanceELISA3-13 ng/mLBlocking Elisa1-5 μg/mLPurification
Protein A purified.
Aggregation
Less than 5%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.03% PF68, with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Bevacizumab was quantified using a PK sandwich ELISA with Monoclonal Anti-Bevacizumab Antibody, Mouse IgG1 (AY10) (Cat. No. BEB-Y10) at 2 μg/mL as the capture antibody and biotinylated Monoclonal Anti-Bevacizumab Antibody, Mouse IgG1 (AY13) (Cat. No. BEB-BY13) at 2 μg/mL as the detection antibody. Bevacizumab standards were prepared in 10% human serum. Detection was performed using HRP-conjugated streptavidin (QC tested).
Protocol
Immobilized bevacizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) with a linear range of 0.78-25 ng/mL (Routinely tested).
Protocol
The ability of Biotinylated Monoclonal Anti-Bevacizumab Antibody, Mouse IgG1 (AY13) (Cat. No. BEB-BY13) to block Bevacizumab to VEGF165 was evaluated by ELISA. VEGF165 was immobilized at 1 μg/mL (100 μL/well). Increasing concentrations of AY13 were tested for their ability to inhibit the biotinylated human VEGF165 to Bevacizumab. AY13 inhibited Bevacizumab binding to VEGF165 in a dose-dependent manner, with an IC₅₀ of approximately 1.03 μg/mL under the tested conditions (Routinely tested).
Protocol
The specificity of Biotinylated Monoclonal Anti-Bevacizumab Antibody, Mouse IgG1 (AY13) (Cat. No. BEB-BY13) was evaluated by ELISA. Bevacizumab was immobilized at 1 μg/mL (100 μL/well). AY13 specifically recognized Bevacizumab, with no detectable binding to the tested human IgG1 controls, Adalimumab, Cetuximab, or VEGF165 under the tested conditions (Routinely tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Contact Us
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
Drug Candidate Licensing
